The purpose of this study is to determine whether combined chemotherapy [rituximab plus high
dosage methotrexate (max. 2 cycles) followed by arabinoside/thiotepa (max. 2 cycles) followed
by high dosage carmustin/thiotepa] followed by peripheral blood stem cell transplantation is
effective in the treatment of cerebral Non Hodgkin lymphoma [PCNSL].